ECE2023 Eposter Presentations Diabetes, Obesity, Metabolism and Nutrition (355 abstracts)
The impact of type 2 diabetes on the post-COVID period according to the ACTIV SARS-CoV-2 registry
Alexander Arutyunov 1,2 , Iuliia Fedorova 3 , Roman Bashkinov 4 , Tatiana Batluk 3 , Evgenii Melnikov 4 , Marina Trubnikova 5 & Elizaveta Gordeychuk 3
1National Institute of Health after academician S. Avdalbekyan, Erevan, Armenia; 2Eurasian Association of Internal Medicine, "ACTIV SARS-CoV-2" Working Group, Erevan, Armenia; 3Eurasian Association of Internal Medicine, "ACTIV SARS-CoV-2" Working Group, Moscow, Russia; 4Eurasian Association of Internal Medicine, "ACTIV SARS-CoV-2" Working Group, Saint Petersburg, Russia; 5Eurasian Association of Internal Medicine, "ACTIV SARS-CoV-2" Working Group, Sochi, Russia
Background: SARS-CoV-2 profoundly impacts population health through both acute infection and post-COVID period. Multiple studies make it clear that metabolic diseases can significantly affect the course of COVID-19.
Aim: To study the course of post-COVID period in patients with type 2 diabetes mellitus (DM2).
Methods: The international registry ACTIV SARS-CoV-2 (NCT04492384) was established to study COVID-19 in the Eurasian region. The post-COVID period was assessed based on telephone surveys of the patients 3 months (n=3083), 6 months (n=2485) and 12 months (n=1774) after recovery. DM2 was reported in 14.3% (n=441), 15% (n=373) and 14.2% (n=252) of all respondents, respectively.
Results: One or more complaints/symptoms (general weakness, dyspnea, unstable blood pressure, arrythmia, cough, thoracalgia, arthralgia, olfaction disorders, myalgia, lower limb edema) persisted more often in patients with DM2 compared to patients without DM2 within 12 months after recovery. At the same time, the proportion of patients with complaints/symptoms gradually increased over time (Table 1). Sub-analysis of 1416 patients at 3 months, 1110 patients at 6 months, and 702 patients at 12 months after recovery demonstrated that DM2 was associated with more unscheduled care visits after recovery (Table 2). Finally, mortality was elevated, and the adverse outcome rate was the highest in patients with type 2 diabetes at 12 months after recovery (Table 3).
| 3 months | 6 months | 12 months | ||||
| No complaints/symptoms | Persisting complaints/symptoms | No complaints/symptoms | Persisting complaints/symptoms | No complaints/symptoms | Persisting complaints/symptoms | |
| Without DM2, n | 1201 (89.8%) | 1441 (82.5%) | 1088 (88.5%) | 1024 (81.6%) | 965 (88.7%) | 557 (81.2%) |
| With DM2, n | 136 (10.2%) | 305 (17.5%)* | 142 (11.5%) | 231 (18.4%)* | 123 (11.3%) | 129 (18.8%)* |
| Note: *P<0.001. | ||||||
| 3 months | 6 months | 12 months | ||||
| No visits | At least 1 visit | No visits | At least 1 visit | No visits | At least 1 visit | |
| Without DM2, n | 255 (89.2%) | 911 (80.6%) | 209 (90.1%) | 681 (77.6%) | 217 (87.9%) | 366 (80.4%) |
| With DM2, n | 31 (10.8%) | 219 (19.4%)* | 23 (9.9%) | 197 (22.4%)* | 30 (12.1%) | 89 (19.6%)** |
| Note: *P<0.001, **P=0.011. | ||||||
| 3 months | 6 months | 12 months | ||||
| Survived | Died | Survived | Died | Survived | Died | |
| Without DM2, n | 2642 (85.7%) | 43 (74.1%) | 2112 (85.0%) | 12 (92.3%) | 1522 (85.8%) | 5 (41.7%) |
| With DM2, n | 441 (14.3%) | 15 (25.9%)* | 373 (15.0%) | 1 (7.7%)** | 252 (14.2%) | 7 (58.3%)*** |
| Note: *P=0.022, **P=0.520, ***P=0.001. | ||||||
Conclusion: DM2 in COVID-19 patients contributes to longer persistence of complaints/symptoms, need for unscheduled medical care, and mortality within 12 months after recovery. These findings call for active monitoring, a more detailed examination, and rehabilitation of patients with DM2 in the post-COVID period.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more